X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (257) 257
Publication (18) 18
Conference Proceeding (12) 12
Book / eBook (5) 5
Book Chapter (2) 2
Book Review (1) 1
Dissertation (1) 1
Magazine Article (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (87) 87
oncology (52) 52
index medicus (45) 45
female (41) 41
male (38) 38
hematology (35) 35
chemotherapy (34) 34
middle aged (32) 32
adult (31) 31
aged (25) 25
cancer (20) 20
animals (16) 16
aged, 80 and over (15) 15
carcinoma, non-small-cell lung - drug therapy (15) 15
lung cancer (15) 15
lung neoplasms - drug therapy (15) 15
therapy (15) 15
treatment outcome (15) 15
medicine & public health (14) 14
analysis (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
lung neoplasms - pathology (12) 12
neoplasm staging (12) 12
adolescent (11) 11
prognosis (11) 11
acute myeloid-leukemia (10) 10
carcinoma, non-small-cell lung - pathology (10) 10
care and treatment (10) 10
expression (10) 10
lung cancer, non-small cell (10) 10
mice (10) 10
non-small cell lung cancer (10) 10
respiratory system (10) 10
carboplatin (9) 9
child, preschool (9) 9
disease-free survival (9) 9
mutation (9) 9
paper (9) 9
radiotherapy (9) 9
research (9) 9
survival (9) 9
acute myelogenous leukemia (8) 8
antineoplastic agents - therapeutic use (8) 8
child (8) 8
lymphomas (8) 8
obstetrics & gynecology (8) 8
patients (8) 8
prospective studies (8) 8
radioimmunotherapy (8) 8
acute disease (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
base sequence (7) 7
biochemistry & molecular biology (7) 7
cancer research (7) 7
cancer therapies (7) 7
diagnosis (7) 7
differentiation (7) 7
infant (7) 7
leukemia, myeloid, acute - genetics (7) 7
molecular sequence data (7) 7
special section (7) 7
tumors (7) 7
chemistry, multidisciplinary (6) 6
clinical trials (6) 6
cloud computing (6) 6
combined modality therapy (6) 6
flow cytometry (6) 6
leukemia (6) 6
metastasis (6) 6
open-label (6) 6
pemetrexed (6) 6
phase-iii (6) 6
reproductive biology (6) 6
resistance (6) 6
retrospective studies (6) 6
risk factors (6) 6
spectroscopy (6) 6
time factors (6) 6
trial (6) 6
young adult (6) 6
1st-line treatment (5) 5
antineoplastic agents (5) 5
cell lung-cancer (5) 5
dna-binding proteins - genetics (5) 5
dose-response relationship, drug (5) 5
dynamics (5) 5
erlotinib (5) 5
follow-up studies (5) 5
germany (5) 5
gynecology (5) 5
histone-lysine n-methyltransferase (5) 5
immunotherapy (5) 5
infant, newborn (5) 5
internal medicine (5) 5
kaplan-meier estimate (5) 5
lung neoplasms - therapy (5) 5
lymphoma (5) 5
minimal residual disease (5) 5
models, molecular (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 12/2017, Volume 142, Issue 24, pp. 1808 - 1812
Was ist neu? Molekulare Alterationen  Neben den bekannten molekularen Alterationen (EGFR; ALK und ROS), die vor Beginn einer Erstlinientherapie in... 
Klinischer Fortschritt
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 12/2017, Volume 142, Issue 24, pp. 1808 - 1812
Journal Article
1958, McGraw-Hill consultant reports on current business problems, 107 leaves.
Book
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1036 - 1047
Summary Background High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma. The role of whole brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | DEFERRED RADIOTHERAPY | 1ST-LINE TREATMENT | ONCOLOGY-GROUP | COMBINED-MODALITY THERAPY | ONCOLOGY | CONSOLIDATION RADIOTHERAPY | CELL TRANSPLANTATION | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | CHEMOTHERAPY | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma - mortality | Antimetabolites, Antineoplastic - administration & dosage | Central Nervous System Neoplasms - radiotherapy | Lymphoma - drug therapy | Time Factors | Dose Fractionation | Female | Lymphoma - radiotherapy | Radiotherapy, Adjuvant | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Chi-Square Distribution | Cranial Irradiation - adverse effects | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Methotrexate - administration & dosage | Aged | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Germany | Chemotherapy | Radiation | Product development | Lymphomas | Methotrexate | Radiotherapy | Biometry | Cancer
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S156 - S157
Journal Article
Karger Kompass Onkologie, ISSN 2296-5416, 2016, Volume 3, Issue 2, pp. 57 - 58
Journal Article
Karger Kompass Onkologie, ISSN 2296-5416, 11/2016, Volume 3, Issue 2, pp. 57 - 58
Journal Article
Acta Neuropathologica, ISSN 0001-6322, 06/2013, Volume 125, Issue 6, pp. 795 - 813
Journal Article
Klinikarzt, ISSN 0341-2350, 04/2016, Volume 45, Issue 3, pp. 140 - 147
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
MEDICINE, GENERAL & INTERNAL | CERITINIB | EML4-ALK FUSION GENE | RESISTANCE | OPEN-LABEL | KINASE INHIBITOR | SINGLE-ARM | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2017, Volume 12, Issue 11, pp. e186 - e188
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 01/2019, Volume 31, Issue 1, pp. 1 - 7
PURPOSE OF REVIEWEpidermal growth factor receptor (EGFR) mt+ nonsmall cell lung cancer (NSCLC) were the first molecularly described NSCLC with an established... 
CARBOPLATIN-PACLITAXEL | SURVIVAL | GEFITINIB | MULTICENTER | epidermal growth factor receptor | PHASE-III | T790M | OPEN-LABEL | chemotherapy | mutation | ONCOLOGY | MUTATIONS | AFATINIB | antiangiogenesis | ERLOTINIB | Lung cancer, Non-small cell | Drug therapy | Research
Journal Article